Penumbra, Inc. (PEN) P/E Ratio History
Deep ValueTrading at 70.7x · 15th percentile of 5-year range · Significant discount to historical valuation · Data 2015–2026
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, Penumbra, Inc. (PEN) trades at a price-to-earnings ratio of 70.7x, with a stock price of $319.44 and trailing twelve-month earnings per share of $4.06.
The current P/E is 83% below its 5-year average of 420.5x. Over the past five years, PEN's P/E has ranged from a low of 60.6x to a high of 1915.5x, placing the current valuation at the 15th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, PEN trades at a 198% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.
Relative to the broader market, PEN commands a significant premium over the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PEN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PEN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PEN P/E vs Peers
Neuromodulation and neuro devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $141B | 50.6 | 2.33 | +23% | |
| $4B | 85.1 | 56.97 | +104% | |
| $1B | 6.1Lowest | 0.59Best | +817%Best | |
| $105B | 32.5 | 2.19 | +8% | |
| $66B | 23.0 | - | +55% | |
| $115B | 23.9 | 3.42 | +3% | |
| $50B | 47.4 | 6.70 | -74% | |
| $18B | 25.6 | - | -20% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PEN Historical P/E Data (2015–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $315.75 | $4.07 | 77.6x | -87% |
| FY2026 Q1 | - | $328.37 | $4.34 | 75.7x | -87% |
| FY2025 Q4 | Dec 31 2025 | $310.91 | $4.52 | 68.8x | -88% |
| FY2025 Q3 | - | $253.32 | $4.18 | 60.6x | -90% |
| FY2025 Q2 | Jun 30 2025 | $256.63 | $3.76 | 68.3x | -88% |
| FY2025 Q1 | Mar 31 2025 | $267.41 | $1.06 | 252.3x | -56% |
| FY2024 Q4 | - | $237.48 | $0.34 | 698.5x | +21% |
| FY2024 Q3 | Sep 30 2024 | $194.31 | $0.86 | 225.9x | -61% |
| FY2024 Q2 | Jun 30 2024 | $179.97 | $0.34 | 529.3x | -8% |
| FY2024 Q1 | Mar 31 2024 | $223.18 | $2.37 | 94.2x | -84% |
| FY2023 Q4 | Dec 31 2023 | $251.54 | $2.31 | 108.9x | -81% |
| FY2023 Q3 | Sep 30 2023 | $241.91 | $1.03 | 234.9x | -59% |
| FY2023 Q2 | Jun 30 2023 | $344.06 | $0.74 | 465.1x | -20% |
| FY2023 Q1 | Mar 31 2023 | $278.69 | $0.16 | 1718.2x | +197% |
| FY2021 Q4 | Dec 31 2021 | $287.32 | $0.15 | 1915.5x | +231% |
| FY2021 Q3 | - | $266.50 | $0.91 | 292.9x | -49% |
| FY2021 Q2 | Jun 30 2021 | $274.06 | $0.43 | 637.3x | +10% |
| FY2020 Q2 | - | $178.82 | $0.29 | 616.6x | +7% |
| FY2020 Q1 | - | $161.33 | $1.09 | 148.0x | -74% |
| FY2019 Q4 | - | $164.27 | $1.35 | 121.7x | -79% |
| FY2019 Q3 | Sep 30 2019 | $134.49 | $1.26 | 106.7x | -82% |
| FY2019 Q2 | Jun 30 2019 | $160.00 | $0.39 | 410.3x | -29% |
| FY2019 Q1 | Mar 31 2019 | $147.01 | $0.30 | 490.0x | -15% |
| FY2018 Q4 | Dec 31 2018 | $122.20 | $0.15 | 814.7x | +41% |
| FY2018 Q3 | Sep 30 2018 | $149.70 | $0.22 | 680.5x | +18% |
| FY2018 Q2 | Jun 30 2018 | $138.15 | $0.78 | 177.1x | -69% |
| FY2018 Q1 | Mar 31 2018 | $115.65 | $0.36 | 318.5x | -45% |
| FY2017 Q4 | Dec 31 2017 | $94.10 | $0.11 | 819.7x | +42% |
| FY2016 Q3 | Sep 30 2016 | $75.99 | $0.05 | 1620.3x | +180% |
| FY2016 Q2 | - | $59.50 | $0.11 | 547.4x | -5% |
| FY2016 Q1 | - | $46.00 | $0.01 | 3382.4x | +485% |
| FY2015 Q4 | - | $53.81 | $0.09 | 597.9x | +3% |
| FY2015 Q3 | Sep 30 2015 | $40.10 | $0.06 | 709.7x | +23% |
Average P/E for displayed period: 578.3x
PEN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PEN — Frequently Asked Questions
Quick answers to the most common questions about buying PEN stock.
What is PEN's P/E ratio?
Penumbra, Inc. (PEN) trailing twelve-month P/E ratio is 70.7x, based on TTM diluted EPS of $4.06. The 5-year average P/E is 420.5x and the historical range spans 60.6x to 1915.5x.
Is PEN stock overvalued or undervalued?
PEN trades at 70.7x P/E, below its 5-year average of 420.5x. At the 15th percentile of its historical range (60.6x–1915.5x), the stock is priced at a discount to its own history.
Is PEN stock expensive?
No, PEN is not expensive on a historical basis. The current P/E of 70.7x is below the 5-year average of 420.5x and sits at the 15th percentile of its valuation range.
What is PEN's historical P/E range?
Over the past 5 years, PEN's P/E ratio has ranged from 60.6x to 1915.5x, with a median of 234.9x and an average of 420.5x. The current P/E of 70.7x places the stock at the 15th percentile of this range. Full historical data spans 2015–2026.
How does PEN's P/E compare to the S&P 500?
PEN trades at 70.7x P/E versus the S&P 500 median of 25.3x. The 179% premium to the market typically reflects higher expected earnings growth or quality.
How does PEN's valuation compare to Healthcare peers?
Penumbra, Inc. P/E of 70.7x compares to the Healthcare sector median of 23.7x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PEN's PEG ratio?
PEN PEG ratio is N/A, based on a P/E of 70.7x and EPS growth of 1155.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is PEN's earnings yield?
PEN earnings yield is 1.42%, the inverse of its 70.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.